1h Free Analyst Time
The liver cirrhosis therapeutics market is forecasted to grow by USD 1.94 bn during 2023-2028, accelerating at a CAGR of 5.58% during the forecast period. The report on the liver cirrhosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of liver cancer, advancements in medical research, and increasing collaborations between pharmaceutical companies and healthcare providers.
The liver cirrhosis therapeutics market is segmented as below:
By Type
- Oral
- Injection
By End-user
- Hospitals
- Clinics
- Research and academic institutes
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the liver cirrhosis therapeutics market covers the following areas:
- Liver cirrhosis therapeutics market sizing
- Liver cirrhosis therapeutics market forecast
- Liver cirrhosis therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global liver cirrhosis therapeutics market: AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is trend towards personalized medicine.`
According to the report, one of the major drivers for this market is the increasing incidence of liver cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- CSL Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Gwo Xi Stem Cell Applied Technology
- Johnson and Johnson
- Kezar Life Sciences Inc.
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Protagonist Therapeutics Inc.
- Tessera Therapeutics
